• Wondering whether Rhythm Pharmaceuticals at US$86.13 still makes sense for your portfolio, or if the recent price leaves little margin for value?
• The stock has pulled back by 0.2% over the last week and 7.4% over the last month, while the 1‑year return sits at 48.9% and the 5‑year return at 315.3%.
• Recent coverage has focused on Rhythm Pharmaceuticals as a specialist in rare genetic disorders, with attention on how its approved therapy and commercial rollout are shaping expectations. Investors have also been watching updates on its clinical pipeline and partnerships, which help frame how much optimism may already be reflected in the share price.
• Simply Wall St currently assigns Rhythm Pharmaceuticals a valuation score of 3 out of 6. The rest of this article will unpack how different valuation approaches arrive at that result, and will also outline a more complete way to think about value at the end.

Approach 1: Rhythm Pharmaceuticals Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model projects a company’s future cash flows and then discounts those back to today’s dollars to estimate what the business might be worth right now.

For Rhythm Pharmaceuticals, the latest twelve month free cash flow (FCF) is a loss of $157.40 million. Analyst estimates and Simply Wall St extrapolations point to FCF of $725.33 million in 2030, with interim projections moving from a loss in 2026 and 2027 to positive FCF from 2028 onward. These figures are all in US$ and use a 2 Stage Free Cash Flow to Equity model, where the first years follow more detailed forecasts and later years are extrapolated.

When all projected cash flows are discounted back, the model arrives at an estimated intrinsic value of $426.55 per share. Against the current share price of US$86.13, this implies the stock is 79.8% undervalued based on these inputs and assumptions.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Rhythm Pharmaceuticals is undervalued by 79.8%. Track this in your watchlist or portfolio, or discover 62 more high quality undervalued stocks.

Approach 2: Rhythm Pharmaceuticals Price vs Sales

For companies where profits are still limited or losses are present, the P/S ratio is often more useful than P/E. It compares the market value directly with current revenue rather than earnings that may be negative or volatile.

In general, higher expected growth and lower perceived risk can justify a higher P/S ratio, while slower growth or greater uncertainty usually point to a lower, more conservative multiple. For Rhythm Pharmaceuticals, the current P/S ratio is 30.99x. This is above the Biotechs industry average of 11.44x and also above the peer average of 7.08x, so on a simple comparison the shares trade at a richer revenue multiple than many peers.

Simply Wall St introduces a “Fair Ratio” to refine this picture. This is the P/S multiple that might be expected once factors such as earnings growth, industry, profit margin, market cap and company specific risks are considered together. Because it blends these elements, it can be more informative than a headline comparison with peers or the sector alone. For Rhythm Pharmaceuticals, the Fair Ratio is 17.23x, which sits well below the current 30.99x and suggests the shares trade above this model based yardstick.

Result: OVERVALUED

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your Rhythm Pharmaceuticals Narrative

Earlier it was mentioned that there is an even better way to understand valuation, so Narratives are introduced here as simple, configurable stories that let you spell out your view on Rhythm Pharmaceuticals future revenue, earnings and margins, link that story to a forecast and fair value, and then compare it with the current price using an easy tool on Simply Wall St’s Community page that updates as news or earnings arrive. This helps you decide whether the shares look attractive or expensive against your own assumptions, and whether you lean closer to the higher fair value around US$158 or the more cautious view near US$105.

Do you think there's more to the story for Rhythm Pharmaceuticals? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.